Food technology specialist Provexis (AIM: PXS) said the authorisation process by the European Commission for the use of a health claim for its Fruitflow anti-thrombotic technology was now in an advanced stage, expecting to make an announcement as soon as the process concludes.
Fruitflow became the first technology to have a health claim approved by the European Food Safety Authority under Article 13(5) of Regulation (EC) No 1924/2006 on nutrition and health claims made on food. The European Commission has since been in an ongoing period of review as it considers the health claim wording for Fruitflow which may be used on end consumer products under the regulation.
Fruitflow is a dietary supplement which will inhibit several pathways of platelet aggregation without side effects. With the Fruitflow technology, Provexis aims to provide a daily dietary supplement with a significant effect on blood flow, but without completely suppressing platelet aggregation.
In an ongoing trial, Fruitflow showed up to 28% reduction from baseline platelet aggregation occurring through three different biological pathways, while aspirin showed up to 60% reduction in one of these pathways, but no effect on the other two. The trial, which is carried out by the company at the Rowett Institute of Nutrition and Health, part of the University of Aberdeen, will continue until the end of the year.
Shares in the company rallied 18% to 7.30 pence on the news this morning.